Chemistry Building Renovation, Construction Will Create New Collaborative Learning Spaces – University of Arizona Provost

University Communications

Tuesday

Work is underway on a $42 million renovation to the University of Arizona's historic Chemistry Building and construction of a new building called The Commons that's dedicated to collaborative learning.

UArizona officials welcomed dozens of guests on Tuesday for a groundbreaking ceremony at the work site on the south side of the University of Arizona Mall.

The combined 78,600-square-foot facilities will be the future home of classrooms designed to encourage cooperation, inclusive practices, and active learning to increase student and faculty engagement and help students develop workplace-relevant skills.

Spread between the new building and renovated Chemistry Building, known affectionately as Old Chem, will be seven collaborative classrooms that range in size from 30 to 200 seats.

"From the beginning, when we first revealed our strategic plan, we had our sights on renovating and reimagining the Old Chem Building into learning spaces that would support collaborative and flexible teaching," University of Arizona President Robert C. Robbins told attendees at the groundbreaking. "We are investing in initiatives that encourage active teaching and learning practices, and this renovation is part of our goal to develop spaces on campus that leverage this interactive and holistic approach to teaching and learning."

In addition to four collaborative classrooms, the renovated Chemistry Building will contain departmental and advising offices and numerous workspaces for Department of Chemistry and Biochemistry faculty; renovated space for nuclear magnetic resonance equipment and electronic and metal shops; a new General Education Office; and three teaching studios for online instruction.

"The renovation of the Old Chem Building will support theCollege of Science, chemistry and biochemistry department, and University of Arizona campus missions to provide high quality education and advance research," said Carmala Garzione, Dean of the College of Science. "The renovation includesstate-of-the-art core research facilities that researchers and students across campus can access.There will be a visualization cave for immersive virtual reality learning.The renovation also will enable the expansion of the world-renowned, award-winning 'Chemical Thinking' education program that transformed chemical education at the University of Arizona and across the country.

The project aligns with the first pillar of UArizona's strategic plan the "Wildcat Journey" by providing additional space for innovative teaching and learning that will prepare UArizona students to find solutions to the greatest challenges facing Arizona and beyond. It also extends the university's Undergraduate STEM Education Project, which since 2014 has transformed dozens of traditional classrooms on campus into collaborative learning spaces, intended to engage students in more active learning with features such as flexible seating arrangements and cutting-edge classroom technologies.

"The University of Arizona is strongly committed to world-class teaching and engaged student learning. The institution supports the Office of Instruction and Assessment and the Office of Digital Learning, and the 60-plus professionals from these units who work with faculty and graduate students to provide professional development in the use of the best teaching practices. Similarly, the university supports technology and classroom renewal, and since 2014, this has included transformation of 37 classrooms for collaborative learning," said Liesl Folks, university senior vice president for academic affairs and provost."Seven collaborative classrooms that facilitate engaged and active learning will be housed in the renovated and new building. In these spaces, faculty members are using innovative teaching and learning strategies that promote higher-order thinking that leads to better understanding and an improved ability to transfer knowledge to other applications."

Tuesday's groundbreaking also included the burial of a time capsule. People at the ceremony were invited to add notes or mementos to a metal container. A plaque will be installed on site when construction is complete, directing future generations where to retrieve the container if and when subsequent construction replaces the new structure.

The renovation and construction project aims to maintain historic elements of the original Chemistry Building, which was designed in 1936 by legendary architect Roy Place, who served as the university's chief architect from 1924 to 1940 and designed eight building on campus, including the Steward Observatory, Administration Building and Gila and Yuma dorms.

"The reimagining of the Chemistry Building and design of the new teaching facility breathes new life into an important building on campus that will evolve with the changing landscape of education and serve the university well through the 21st century," said Alison Rainey, principal architect at Shepley Bulfinch, the firm that designed the new building. "The new design creates flexible and adaptable classrooms for teaching and learning with integrated technology and a variety of collaborative environments."

"Space is an important partner in the teaching and learning experience. The physical layout of a classroom impacts the pedagogy, and when you walk into a collaborative classroom, you realize that something interesting happens in the space," said Gail Burd, senior vice provost for academic affairs, teaching and learning.

"The furniture is arranged for small-group student engagement and for problem solving or creative thinking. In large collaborative classrooms, the best instructors make use of undergraduate learning assistants who have previously taken the course and enjoy helping other students learn the material," said Burd, also a Distinguished Professor of Molecular and Cellular Biology. "In turn, the learning assistants gain a deeper understanding of the course concepts. Instructors can also use formative assessment of student learning by engaging in discussion with different groups of students around the classroom and then, can adjust their instruction to improve learning."

Sundt Construction crews began work in May, demolishing much of the interior of the Chemistry Building to make way for new construction, while leaving untouched the original facade on the north side of the building to retain the aesthetic character of the University of Arizona Mall, and portions of a 1948 buildingexpansion.

Project managers expect the work to run through December 2022.

Read more:
Chemistry Building Renovation, Construction Will Create New Collaborative Learning Spaces - University of Arizona Provost

Job Dekker and Katherine Fitzgerald elected to National Academy of Medicine – UMass Medical School

UMass Chan Medical School scientists Job Dekker, PhD, and Katherine A. Fitzgerald, PhD, have been elected to the National Academy of Medicine for their distinguished contributions to medicine and health.

According to National Academy of Medicine President Victor J. Dzau, MD, who received an honorary degree from the Medical School in 2015, this is the academys most diverse class of new members, comprising approximately 50 percent women and 50 percent racial and ethnic minorities. This class represents many identities and experiencesall of which are absolutely necessary to address the existential threats facing humanity. I look forward to working with all of our new members in the years ahead, said Dr. Dzau.

New members are elected by current members through a process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care and public health.

Dr. Dekker, Howard Hughes Medical Institute investigator, the Joseph J. Byrne Chair in Biomedical Research, professor of biochemistry & molecular pharmacology and systems biology, was recognized for introducing the groundbreaking concept that matrices of genomic interactions can be used to determine chromosome conformation.

The Dekker lab studies how a genome is organized in three dimensions inside the nucleus. Although DNA is composed of a linear sequence of bases, it doesnt exist inside the cell nucleus in a simple, straight line. More like a ball of cooked spaghetti, the genome folds and loops back on itself so it can fit inside the tight confines of the nucleus. The shape it takes has a profound influence on which genes in a cell are turned on or turned off, and as a consequence, on health and disease. Many diseases, including cancer, are characterized by alterations in the spatial organization of the genome. This 3D architecture varies from cell type to cell type and even between cell states.

To study this 3D structure, Dekker developed chromosome conformation capture technologies, biochemical techniques for determining how DNA segments interact and are linked to one another. This technology is the heart of the 3C, 5C, Hi-C and Micro-C tools used by researchers worldwide to map the structure and organization of chromosomes inside cells.

Dekker received his PhD from Utrecht University in 1997 and joined UMass Chan in 2003.

Dr. Fitzgerald, the Worcester Foundation for Biomedical Research Chair, professor of medicine, vice chair for research in the Department of Medicine and director of the Program in Innate Immunity, was named to the academy for her pioneering work on innate immune receptors, signaling pathways and regulation of inflammatory gene expression.

Research in the Fitzgerald lab is focused on understanding the molecular mechanisms controlling the inflammatory process. Fitzgerald and her team use immunology, biochemistry, molecular biology and genetics to determine how the immune system discriminates between pathogens and host molecules to both protect the host from infection and avoid damaging inflammatory diseases. Fitzgerald has made numerous novel discoveries, including the identification of Toll-like receptor adapter molecules; TANK binding kinase-1 (TBK1) as the IRF3 kinase; identification of the AIM2 inflammasome; defined key regulators of the NLRP3 inflammasome; and uncovered new evidence for the importance of long-coding RNAs in innate immunity.

Fitzgerald, who joined the faculty in 2004, has a bachelors degree in biochemistry from University College Cork, and a PhD from Trinity College Dublin. She was elected to the American Academy of Microbiology in 2020 and the National Academy of Sciences in 2021.

The National Academy of Medicine, formerly the Institute of Medicine, was established in 1970 under the charter of the National Academy of Sciences to advise the nation on medical and health issues.

The National Academy of Medicine works together with the National Academy of Sciences and National Academy of Engineering to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The academies also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science, engineering and medicine.

Related stories on UMassMed News:UMass Chan Medical School establishes new Department of Systems BiologyUMMS scientists to expand 4D nucleome research with $13 million NIH grantsKatherine Fitzgerald and Nikolaus Grigorieff elected to National Academy of Sciences

Excerpt from:
Job Dekker and Katherine Fitzgerald elected to National Academy of Medicine - UMass Medical School

Merck Foundation to fund professorships for early-career physician-scientists Washington University School of Medicine in St. Louis – Washington…

Visit the News Hub

Gift aimed at supporting School of Medicine researchers from populations underrepresented in medicine, biomedical sciences

The Merck Foundation has made a $2 million commitment to Washington University School of Medicine in St. Louis to establish two endowed assistant professorships each a Roger M. Perlmutter Career Development Professorship to support early-career physician-scientists from populations that are historically underrepresented in medicine and biomedical sciences. The professorships are named for Roger M. Perlmutter, MD, PhD, (pictured), a graduate of Washington Universitys Medical Scientist Training Program and, later, head of research and development at Merck. Monica Chang-Panesso, MD, an assistant professor of medicine, will receive the first such professorship.

The Merck Foundation has made a $2 million commitment to Washington University School of Medicine in St. Louis to establish two endowed assistant professorships supporting early-career physician-scientists from populations that are historically underrepresented in medicine and biomedical sciences.

Named for Roger M. Perlmutter, MD, PhD, a graduate of Washington Universitys Medical Scientist Training Program who later went on to lead research and development at Merck, the professorships will help advance the work of assistant professors pursuing promising medical research.

Chang-Panesso

The first Roger M. Perlmutter Career Development Professorship will be awarded to Monica Chang-Panesso, MD, an assistant professor of medicine in the Division of Nephrology. Another School of Medicine faculty member will be chosen for a second Perlmutter professorship in the near future.

The experience that I had at Washington University School of Medicine was transformational; the six years that I spent there made all the difference in terms of my ability to pursue a career in science and in drug discovery, Perlmutter said. Time and again, Washington University School of Medicine, in its teaching mission, its research mission and its mission of clinical translation, has done more than other academic medical centers to advance the cause of medical practice. I am deeply honored to have this gift from the Merck Foundation, which bears my name, to help further the cause of this great academic medical center.

The new career development professorships will provide support for faculty from populations underrepresented in medicine as they build their research programs. Once a recipient achieves tenure and transitions to the next career level, the professorship will be awarded to another faculty member.

Helping to create opportunities for physician-scientists to focus on research and develop as investigators is deeply important to the School of Medicine and is one of the core values that has distinguished WashU for many decades, said David H. Perlmutter, MD, the George and Carol Bauer Dean of the School of Medicine, executive vice chancellor for medical affairs, and the Spencer T. and Ann W. Olin Distinguished Professor. By providing support in the critical early phases of the career,these professorships, which are also enhanced by the prestige of Dr. Roger M. Perlmutters many career accomplishments as a physician-scientist, will better position us to addressthe urgent need for more physician-scientists from populations that historically have been excluded from medicine.

Li

Dean Y. Li, MD, PhD, Merck executive vice president and president of Merck Research Laboratories, and successor to Roger M. Perlmutter at Merck, explained that the Merck Foundation decided to honor Roger M. Perlmutters career by making a gift in his name to an institution with which he holds a long and proud association. Providing support to boost the careers of young physician-scientists seemed more than fitting.

The physician-scientist is critical for an academic medical center such as WashU, said Li, also a graduate of the universitys Medical Scientist Training Program. You have the science, and you have your clinical mission. The person who ties that together is the physician-scientist. Focusing on young scientists, especially physician-scientists at the early stages, is where the need is.

Chang-Panesso, the first faculty member named to a Perlmutter professorship, studies molecular mechanisms that impair the regenerative response after acute kidney injury, particularly when, in older people, the kidneys suddenly stop working as they should. Her current research, supported by a five-year grant from the National Institutes of Health (NIH), seeks new therapeutic targets and clinical interventions to improve the success of kidney repair in older patients.

I am very honored to be the recipient of the Roger M. Perlmutter Career Development Professorship, Chang-Panesso said.It is an amazing initiative supporting the career development of underrepresented physician-scientists, and I am very grateful to have been chosen.

Born and raised in Colombia, Chang-Panesso completed her undergraduate and postgraduate training in the United States, including a bachelors degree in biochemistry from the University of Texas at Arlington and a medical degree from the Texas Tech University Health Sciences Center School of Medicine in Lubbock, Texas.

She completed her residency at the University of Texas Southwestern Medical Center at Dallas and a nephrology fellowship at the Brigham and Womens Hospital/Massachusetts General Hospital program in Boston. She joined Washington University as a postdoctoral research scholar in 2015 and was promoted to assistant professor of medicine in 2018.

As a bilingual physician with Hispanic and Chinese roots, she is well aware that the rate of kidney disease is higher among racial and ethnic minorities. She hopes her career as a physician-scientist will help her identify treatments that will make a beneficial impact in these communities.

Roger M. Perlmutter earned his medical and doctoral degrees from Washington University in 1979. A member of the School of Medicine National Council since 2005, he received the universitys Distinguished Alumni Award in 2018.

Perlmutters family includes two more Washington University graduates. His wife, Joan Kreiss, an infectious diseases specialist, earned a medical degree in 1978. His son, Noah, earned an undergraduate degree from Arts & Sciences in 2020.

Before assuming leadership roles in industry, Perlmutter was a professor in the departments of immunology, biochemistry and medicine at the University of Washington, Seattle. He also served as a Howard Hughes Medical Institute investigator and chaired the Department of Immunology there. He is a fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science, and past president of the American Association of Immunologists.

Perlmutter joined Merck Research Laboratories in 1997 as executive vice president of basic and preclinical research. From 2001 to 2012, he served as executive vice president and head of research and development at Amgen. He returned to Merck in 2013, serving as executive vice president and president of Merck Research Laboratories until his retirement in 2020. He became chief executive officer of Eikon Therapeutics, a company that employs super-resolution microscopy to pursue the discovery of new medicines, in 2021.

During his academic and corporate careers, Perlmutter has supervised the discovery, development and subsequent approval of novel medicines addressing major inflammatory and endocrinologic diseases, as well as a breakthrough oncology therapy that works with the immune system to help fight certain types of cancer.

Under his leadership, Merck received more than 100 regulatory approvals for its medicines and vaccines globally, including more than 15 novel vaccines and therapeutics for multiple cancers, diabetes and infections caused by Ebola virus, human immunodeficiency virus, hepatitis C virus and cytomegalovirus.

Washington University School of Medicines 1,700 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, consistently ranking among the top medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Follow this link:
Merck Foundation to fund professorships for early-career physician-scientists Washington University School of Medicine in St. Louis - Washington...

Radioactive metals for medicine get a boost from recently discovered protein | Penn State University – Penn State News

UNIVERSITY PARK, Pa. A protein can be used to recover and purify radioactive metals such as actinium that could be beneficial for next-generation drugs used in cancer therapies and medical imaging, according to new research from Penn State and Lawrence Livermore National Laboratory (LLNL).

Radioactive metals are used in a variety of medical imaging and therapeutic applications. Actinium is a promising candidate for next-generation cancer therapies, and actinium-based therapies have treatment efficacy hundreds of times higher than current drugs. However, the chemistry of this metal is not well understood, and there are several limitations in the supply chain that have kept actinium-based drugs from reaching the market.

In this study, our team took advantage of a protein my lab previously discovered called lanmodulin and showed that it can be used to improve and simplify the recovery and purification of actinium, said Joseph Cotruvo Jr., assistant professor of chemistry at Penn State and an author of the paper. The research team presents their results in a paper appearing Oct. 20 in the journal Science Advances.

A protein can be used to recover and purify radioactive metals such as actinium, pictured here, that could be beneficial for next-generation drugs used in cancer therapies and medical imaging.

IMAGE: Oak Ridge National Laboratory/Wikimedia Commons

Radioactive metals used in medical applications must be purified to extremely high levels through lengthy processes and, to minimize toxicity in the patient, they must form complexes with molecules called chelators that are tailored to bind the radioactive metal ions. The vast majority of these chelators are synthetic molecules that are arrived at through trial and error. In addition to these challenges, the actinium supply chain faces several difficulties. Actinium is extremely rare and must be produced in nuclear reactors or other large instruments, and knowledge of the elements chemistry, which is necessary to develop optimal chelators, is limited.

These challenges exist even for medical isotopes in relatively widespread use, such as radioactive yttrium, but they are even more taxing in the case of actinium, said Gauthier Deblonde, a scientist at LLNL and lead author of the paper.

Because actinium is so rare, research efforts to understand and harness actinium chemistry have thus far focused on reusing or adapting similar known synthetic molecules used in the nuclear chemistry field, but results have been limited. The new research took a drastically different approach, leveraging the natural protein lanmodulin, which is exceptionally good at binding to valuable metals called rare Earth elements. This new strategy not only improves and simplifies the purification processes for actinium but can also be used to recover and detect other radioactive elements, even at extremely low levels.

The team showed how lanmodulin can be used to bind to, recover, and purify actinium (at least 99.5% purity obtained in a single step), as well as another medically relevant radioisotope, yttrium-90, which is used in cancer therapies and diagnostics. The unprecedented efficiency and simplicity of the protein-based approach also allows preparation of actinium at much lower cost and makes probing its chemistry more convenient. The process is likely extendable to many other radioactive isotopes used in radiation therapy and imaging.

Our new technique represents a paradigm shift not just in the development of actinium chemistry and actinium-based pharmaceuticals, but also in nuclear medicine more generally, said Cotruvo.

This study marks the first time actinium has been characterized bound to a protein important knowledge if it may eventually be used inside humans. The researchers found that lanmodulin is so efficient compared to classic molecules that it specifically binds to actinium even in the presence of large quantities of impurities, like radium and strontium, or elements that are common in the body like calcium, zinc and copper. The study also demonstrates that the protein is more effective at binding actinium than binding rare earth elements, the metals it binds to in nature.

Lanmodulins tight and specific binding allowed us to easily access minute quantities of radioactive metals, where traditional technologies based on synthetic chelators fail, Deblonde said. What we accomplished here was simply unfathomable a few years ago. The unique combination of skills in radiochemistry, metal separation, and biochemistry at LLNL and Penn State made this possible.

The research not only offers insights into the fundamental chemistry of actinium but also suggests that the actinium-lanmodulin complex could be the basis for new actinium pharmaceuticals, as lanmodulin in some ways outperforms the synthetic chelators currently used with radioactive metals in the clinic and clinical trials.

We believe that our results unify the fields of metal separations and biochemistry and have strong potential to revolutionize several critical steps in medicinal chemistry from purifying isotopes to delivering therapeutic doses to patients, Cotruvo said.

In addition to Cotruvo and Deblonde, the research team includes Joseph Mattocks, a graduate student at Penn State, and Ziye Dong, Paul Wooddy and Mavrik Zavarin at LLNL. The work is funded by LLNLs Laboratory Directed Research and Development program and the Department of Energy Office of Science.

View original post here:
Radioactive metals for medicine get a boost from recently discovered protein | Penn State University - Penn State News

Genetics and the link to breast cancer | Mobile County Alabama News | fox10tv.com – FOX10 News

'); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); if (val.poly != "" && val.polyimg != "") { $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append('"+val.ihtml+""); $("#expandable-weather-block .weather-index-alerts").show(); $("#expandable-weather-block .modal-body h2").css({"font-family":"'Fira Sans', sans-serif", "font-weight":"500", "padding-bottom":"10px"}); $("#expandable-weather-block .modal-body p").css({"font-size":"14px", "line-height":"24px"}); $("#expandable-weather-block .modal-body span.wxalertnum").css({"float":"left", "width":"40px", "height":"40px", "color":"#ffffff", "line-height":"40px", "background-color":"#888888", "border-radius":"40px", "text-align":"center", "margin-right":"12px"}); $("#expandable-weather-block .modal-body b").css("font-size", "18px"); $("#expandable-weather-block .modal-body li").css({"font-size":"14px", "line-height":"18px", "margin-bottom":"10px"}); $("#expandable-weather-block .modal-body ul").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body pre").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body img").css({"width":"100%", "margin-bottom":"20px", "borderWidth":"1px", "border-style":"solid", "border-color":"#aaaaaa"}); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).css({"borderWidth":"0", "border-bottom-width":"1px", "border-style":"dashed", "border-color":"#aaaaaa", "padding-bottom":"10px", "margin-bottom":"40px"}); }); } function parseAlertJSON(json) { console.log(json); alertCount = 0; if (Object.keys(json.alerts).length > 0) { $("#mrd-wx-alerts .modal-body ").empty(); } $.each(json.alerts, function(key, val) { alertCount++; $("#mrd-wx-alerts .alert_count").text(alertCount); $("#mrd-wx-alerts .modal-body ").append(''); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); if (val.poly != "" && val.polyimg != "") { $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } else if (val.fips != "" && val.fipsimg != "") { // $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(val.dhtml+"

Instruction

Read more:
Genetics and the link to breast cancer | Mobile County Alabama News | fox10tv.com - FOX10 News

What’s Going on With Fulgent Genetics? – The Motley Fool

Fulgent Genetics' (NASDAQ:FLGT) sales soared thanks to its COVID-19 tests. Its stock more than quadrupled in 2020 and is up over 50% so far this year. In this Motley Fool Live video recorded on Sept. 29, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss what's going on now with Fulgent.

Keith Speights: Your thoughts on Fulgent Genetics, ticker is FLGT?

Brian Orelli: The company is still developing genetic tests, which was what they were doing before the pandemic. They're still doing COVID-19 testing, which is what they pivoted or added during the pandemic. Then they are using all that cash that they're getting from the COVID-19 to expand fairly quickly.

They bought a company that does more other types of tests for cancers, looking at imaging the tumors and that thing and looking at the chromosomes. I think that they are using that to expand their offerings, so now that they will be able to do genetic testing on the tumors, but also offer other services. That should make them a one-stop-shop for tumors.

They also did a deal with another company that has a predictive test, I believe, for cancer. They're partnering with that company. The other one was an acquisition where they just bought the whole testing facility to expand their offerings in cancer.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Read the original:
What's Going on With Fulgent Genetics? - The Motley Fool

Epigenetics, the misunderstood science that could shed new light on ageing – The Guardian

A little over a decade ago, a clutch of scientific studies was published that seemed to show that survivors of atrocities or disasters such as the Holocaust and the Dutch famine of 1944-45 had passed on the biological scars of those traumatic experiences to their children.

The studies caused a sensation, earning their own BBC Horizon documentary and the cover of Time (I also wrote about them, for New Scientist) and no wonder. The mind-blowing implications were that DNA wasnt the only mode of biological inheritance, and that traits acquired by a person in their lifetime could be heritable. Since we receive our full complement of genes at conception and it remains essentially unchanged until our death, this information was thought to be transmitted via chemical tags on genes called epigenetic marks that dial those genes output up or down. The phenomenon, known as transgenerational epigenetic inheritance, caught the public imagination, in part because it seemed to release us from the tyranny of DNA. Genetic determinism was dead.

A decade on, the case for transgenerational epigenetic inheritance in humans has crumbled. Scientists know that it happens in plants, and weakly in some mammals. They cant rule it out in people, because its difficult to rule anything out in science, but there is no convincing evidence for it to date and no known physiological mechanism by which it could work. One well documented finding alone seems to present a towering obstacle to it: except in very rare genetic disorders, all epigenetic marks are erased from the genetic material of a human egg and sperm soon after their nuclei fuse during fertilisation. The [epigenetic] patterns are established anew in each generation, says geneticist Bernhard Horsthemke of the University of Duisburg-Essen in Germany.

Even at the time, sceptics pointed out that it was fiendishly difficult to disentangle the genetic, epigenetic and environmental contributions to inherited traits. For one thing, a person shares her mothers environment from the womb on, so that persons epigenome could come to resemble her mothers without any information being transmitted via the germline, or reproductive cells. In the past decade, the threads have become even more tangled, because it turns out that epigenetic marks are themselves largely under genetic control. Some genes influence the degree to which other genes are annotated and this shows up in twin studies, where certain epigenetic patterns have been found to be more similar in identical twins that in non-identical ones.

This has led researchers to think of the epigenome less as the language in which the environment commands the genes, and more as a way in which the genes adjust themselves to respond better to an unpredictable environment. Epigenetics is often presented as being in opposition to genetics, but actually the two things are intertwined, says Jonathan Mill, an epigeneticist at the University of Exeter. The relationship between them is still being worked out, but for geneticist Adrian Bird of the University of Edinburgh, the role of the environment in shaping the epigenome has been exaggerated. In fact, cells go to quite a lot of trouble to insulate themselves from environmental insult, he says.

Whatever that relationship turns out to be, the study of epigenetics seems to reinforce the case that its not nature versus nurture, but nature plus nurture (so genetic determinism is still dead). And whatever the contribution of the epigenome, it doesnt seem to translate across generations.

All the aforementioned researchers rue the fact that transgenerational epigenetic inheritance is still what most people think of when they hear the word epigenetics, because the past decade has also seen exciting advances in the field, in terms of the light it has shed on human health and disease. The marks that accumulate on somatic cells that is, all the bodys cells except the reproductive ones turn out to be very informative about these, and new technologies have made it easier to read them.

Different people define epigenetics differently, which is another reason why the field is misunderstood. Some define it as modifications to chromatin, the package that contains DNA inside the nuclei of human cells, while others include modifications to RNA. DNA is modified by the addition of chemical groups. Methylation, when a methyl group is added, is the form of DNA modification that has been studied most, but DNA can also be tagged with hydroxymethyl groups, and proteins in the chromatin complex can be modified too.

Researchers can generate genome-wide maps of DNA methylation and use these to track biological ageing, which as everyone knows is not the same as chronological ageing. The first such epigenetic clocks were established for blood, and showed strong associations with other measures of blood ageing such as blood pressure and lipid levels. But the epigenetic signature of ageing is different in different tissues, so these couldnt tell you much about, say, brain or liver. The past five years have seen the description of many more tissue-specific epigenetic clocks.

Mills group is working on a brain clock, for example, that he hopes will correlate with other indicators of ageing in the cortex. He has already identified what he believes to be an epigenetic signature of neurodegenerative disease. Were able to show robust differences in DNA methylation between individuals with and without dementia, that are very strongly related to the amount of pathology they have in their brains, Mill says. Its not yet possible to say whether those differences are a cause or consequence of the pathology, but they provide information about the mechanisms and genes that are disrupted in the disease process, that could guide the development of novel diagnostic tests and treatments. If a signal could be found in the blood, say, that correlated with the brain signal theyve detected, it could form the basis of a predictive blood test for dementia.

While Bird and others argue that the epigenome is predominantly under genetic control, some researchers are interested in the trace that certain environmental insults leave there. Smoking, for example, has a clear epigenetic signature. I could tell you quite accurately, based on their DNA methylation profile, if someone was a smoker or not, and probably how much they smoked and how long they had smoked for, says Mill.

James Flanagan of Imperial College London is among those who are exploiting this aspect of the epigenome to try to understand how lifestyle factors such as smoking, alcohol and obesity shape cancer risk. Indeed, cancer is the area where there is most excitement in terms of the clinical application of epigenetics. One idea, Flanagan says, is that once informed of their risk a person could make lifestyle adjustments to reduce it.

Drugs that remodel the epigenome have been used therapeutically in those already diagnosed with cancer, though they tend to have bad side-effects because their epigenetic impact is so broad. Other widely prescribed drugs that have few side-effects might turn out to work at least partly via the epigenome too. Based on the striking observation that breast cancer risk is more than halved in diabetes patients who have taken the diabetes drug metformin for a long time, Flanagans group is investigating whether this protective effect is mediated by altered epigenetic patterns.

Meanwhile, the US-based company Grail which has just been bought, controversially, by DNA sequencing giant Illumina has come up with a test for more than 50 cancers that detects altered methylation patterns in DNA circulating freely in the blood.

Based on publicly available data on its false-positive and false-negative rates, the Grail test looks very promising, says Tomasz K Wojdacz, who studies clinical epigenetics at the Pomeranian Medical University in Szczecin, Poland. But more data is needed and is being collected now in a major clinical trial in the NHS. The idea is that the test would be used to screen populations, identifying individuals at risk who would then be guided towards more classical diagnostic procedures such as tissue-specific biopsies. It could be a gamechanger in cancer, Wojdacz thinks, but it also raises ethical dilemmas, that will have to be addressed before it is rolled out. Imagine that someone got a positive result but further investigations revealed nothing, he says. You cant put that kind of psychological burden on a patient.

The jury is out on whether its possible to wind back the epigenetic clock. This question is the subject of serious inquiry, but many researchers worry that as a wave of epigenetic cosmetics hits the market, people are parting with their money on the basis of scientifically unsupported claims. Science has only scratched the surface of the epigenome, says Flanagan. The speed at which these things happen and the speed at which they might change back is not known. It might be the fate of every young science to be misunderstood. Thats still true of epidenetics, but it could about to change.

Until recently, sequencing the epigenome was a relatively slow and expensive affair. To identify all the methyl tags on the genome, for example, would require two distinct sequencing efforts and a chemical manipulation in between. In the past few years, however, it has become possible to sequence the genome and its methylation pattern simultaneously, halving the cost and doubling the speed.

Oxford Nanopore Technologies, the British company responsible for much of the tracking of the global spread of Covid-19 variants, which floated on the London Stock Exchange last week, offers such a technology. It works by pushing DNA through a nanoscale hole while current passes either side. DNA consists of four bases or letters A, C, G and T and because each one has a unique shape in the nanopore it distorts the current in a unique and measurable way. A methylated base has its own distinctive shape, meaning it can be detected as a fifth letter.

The US firm Illumina, which leads the global DNA sequencing market, offers a different technique, and chemist Shankar Balasubramanian of the University of Cambridge has said that his company, Cambridge Epigenetix, will soon announce its own epigenetic sequencing technology one that could add a sixth letter in the form of hydroxymethyl tags.

Protein modifications still have to be sequenced separately, but some people include RNA modifications in their definition of epigenetics and at least some of these technologies can detect those too meaning they have the power to generate enormous amounts of new information about how our genetic material is modified in our lifetime. Thats why Ewan Birney who co-directs the European Bioinformatics Institute in Hinxton, Cambridgeshire, and who is a consultant to Oxford Nanopore, says that epigenetic sequencing stands poised to revolutionise science: Were opening up an entirely new world.

The rest is here:
Epigenetics, the misunderstood science that could shed new light on ageing - The Guardian

Barriers Prevent Diversity Within Genetics Workforce, But Some Programs Aim to Bolster Representation – GenomeWeb

NEW YORK The lack of diversity within the genetics and genomics workforce not only means that it does not reflect the population it servesbut could also undermine patient care, according to a roundtable discussion organized by the National Academies of Sciences, Engineering, and Medicine.

This lack of diversity is particularly stark among genetic counselors where 90 percent of the workforce is white. Having the workforce better reflect the population it aims to serve the most recent US Census has found that an increasing proportion of the US population identifies as belonging to a minority group will also lead to better patient access and care.

"Having a diverse workforce is not just a nice thing to do," Sylvia Mann, the genomics section supervisor at the Hawaii State Department of Health, said during the roundtable presentations. "There is evidence that having a diverse workforce and student body is really supportive of services to underserved communities."

But there are a number of barriers to increased diversity, including a lack of exposure to the field, few role models, and a lack of support, according to the NASEM roundtable held this week. There are, though, ways to address some of those issues, such as through pathway programs, mentorship, and better reimbursement and pay for genetics professionals.

"Representation matters, and we have to invest in changing the professional profile of those involved in the genomics workforce," Altovise Ewing, a senior science leader at Genentech, added during the roundtable.

The past year has led to an increased focus on issues of diversity, equity, inclusion, and justice across society following the death of George Floyd and subsequent protests. This has prompted organizations like the American Association for the Advancement of Science to look into how to make both itself and the sciences more diverse. Similarly, the US National Human Genome Research Instituterecently announced an initiative to "adopt diversity as an ethos," especially in light of the field's past ties to eugenics.

However, the field has also had to grapple with current signs of overt racism, including incidents that led to the resignation of the outgoing president of the American College of Medical Genetics and Genomicsand theeditor-in-chief of the Journal of the American Medical Association.

The lack of diversity also has effects on patients, according to Ewing, limiting the reach of the benefits gained from genetics and genomics.

Because the workforce is predominately white, most genetic and genomic research has focused on a white, European-ancestry population and on research questions of concern to that population. Recent studies, for instance, have estimated that nearly 80 percent of individualsin genome-wide association studies have been of European ancestry. Such studies, when brought into the clinic, lead to unequal treatment of patients because less is then known about disease-associated variants that may be more common among other ancestry populations, which then affects professional and practice guidelines.

"This translates into inequities in opportunities for patients and families to engage in precision care, preventative screening, and innovative research options that will potentially stop diseases such as cancer in its tracks," Ewing said.

A more diverse workforce may identify research questions of interest and importance to different communities as well as lead to better communication with a diverse patient population through shared experiences and culture.

Addressing barriers

There are many known barriers to healthcare careers, Mann noted, including, for instance, a lack of exposure to fields like genetic counseling, a lack of role models or poor advising, and financial constraints, among others. Admission requirements like shadowing a genetic counselor or great reliance on MCAT scorescan also be a hindrance.

There are, though, ongoing programs aimed at addressing some of these barriers.

Omar Abdul-Rahman, the director of genetic medicine at the Munroe-Meyer Institute at the University of Nebraska Medical Center, for instance, is reaching out to high school students with the UNMC High School Alliance program.

Through the program, about 50 students a year spend about two hours a day on campus where they take classes taught by faculty and also spend about one afternoon a week learning about different career paths. The Omaha public schools are about 36 percent white, 25 percent Black, 26 percent Asian, and 6.5 percent Hispanic or Latino, according to Abdul-Rahman.

"We really need to think about getting that early exposure and going as early as possible because the effects of structural racism really start very, very early in the elementary and high school years," Abdul-Rahman said.

At the same time, Barbara Harrison, a genetic counselor at Howard University College of Medicine, added that pipeline programs linking, for instance, graduate programs in genetic counseling to historically Black colleges and universities or other undergraduate institutions serving underrepresented groups could help reach qualified applicants. She noted that though HBCUs represent 3percent of degree-granting institutions in the US, in 2013 they represented 17 percent of the colleges that supplied the most African American applicants to medical school.

Mentorship programs, Harrison noted, can also help interested college students who are not as familiar with the academic system to navigate the application process and its associated costs.

She added that the Genetics Opportunity Learning Development & Empowerment Networkis focused on increasing the number of Black genetic counselors by both raising awareness about the field and mentoring prospective applicants.

Hawaii's Mann added that programs should also try to ensure they are a safe space for minority students once they do arrive. "We get horrific stories about training programs and experiences in clinical rotations, and things like that are just bad for our minority students," she said.

Part of creating a safe space is to have institutional policies on diversity, equity, inclusion, and justice. This, Mann noted, is more than having an online training module about diversity but involves committing to open communication so students can discuss problems as well as having clear and transparent responses to any issues.

Having diverse faculty also helps to create a safe space, she added, noting that these faculty members can then be the next training program leaders. The Western States Regional Genetics Network, for which Mann serves as the project director, has a Minority Genetic Professionals Network for students, trainees, and professionals. In addition to its mentoring program, it also offers leadership training.

Overall, according to the American Society for Human Genetics' Chazeman Jackson, a roundtable moderator, there is a "societal imperative to bring diversity into genetics and genomics services, [and] the workforce must reflect the world we aim to serve and empower patients with agency. And if that doesn't happen, then we reduce our reach, we stifle our advancements, and we impede inclusion."

Here is the original post:
Barriers Prevent Diversity Within Genetics Workforce, But Some Programs Aim to Bolster Representation - GenomeWeb

Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients – Business Wire

BOSTON--(BUSINESS WIRE)--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Mes 360-degree, validated and evidence-based cancer support and treatment options via its free and easy-to-use app. Initially and currently available in the United States, patients can now receive genetic counseling through Invitaes partnership with Genome Medical, get testing, and upload their results within the Outcomes4Me app.

There is a misconception that genetic testing is only useful as a preventative tool prior to a cancer diagnosis. According to Outcomes4Me patient data, almost half of users (46 percent) who qualified for testing (based on NCCN Guidelines) did not receive testing or did not know if they had received testing. However, genetic testing can provide insights that can help inform and refine precision therapy use and clinical treatment trial enrollment. In addition, genetic testing results can be used to help prevent recurrence and reduce incidence of other inherited cancers.

A cancer diagnosis is often overwhelming for patients and their families. Outcomes4Me demystifies cancer by providing the most up-to-date and validated research, support, and treatment options, all grounded in science and data and curated according to the patients specific diagnosis. Outcomes4Me partners with the researchers, doctors, and academics that set the rigorous standards of cancer care for all treatment providers, including the National Comprehensive Care Network (NCCN), Vanderbilt-Ingram Cancer Center (VICC) and Massachusetts General Hospital (MGH). The collaboration with Invitae expands access to genetic testing, a vitally important tool in the patients cancer care arsenal.

Outcomes4Me is an indispensable platform for patients with breast cancer, giving them the personalized knowledge and access to timely new trials and targeted therapies that could lead to better health outcomes, said Ed Esplin, M.D., Ph.D., FACMG, FACP, Clinical Geneticist at Invitae. By providing access to our comprehensive genetic testing and counseling services, Outcomes4Me is adding a valuable resource that will empower patients to advance their knowledge, understanding, and therefore, self-advocacy during treatment and survivorship.

Unlike popular direct-to-consumer genetic testing services, which test for a few specific genetic variants for certain genes, Invitae provides state-of-the-art clinical grade next-generation sequencing-based (NGS) genetic testing that comprehensively analyses more than 80 genes, including all known mutations of the important BRCA1/BRCA2 genes. This comprehensive approach, combined with associated genetic counseling, not only provides insights for cancer patients, but also for family members who may be at risk.

Our collaboration with Invitae reinforces Outcomes4Mes mission to give patients back control, said Maya R. Said, Sc. D., Founder and CEO of Outcomes4Me. Because of this work with Invitae, our valued community now has rare direct access to a much-needed testing service. Outcomes4Me will proudly continue to democratize the best in cancer treatment, research, and support by removing barriers and bias in information flow.

The Outcomes4Me app is available free to users on both the App Store and Google Play.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at http://www.invitae.com.

About Outcomes4Me

Outcomes4Me is on a mission to improve health outcomes by empowering patients with understandable, relevant and evidence-based information. Outcomes4Me has developed a platform for shared decision-making between patients and providers. The platform harnesses regulatory-grade, real-world data and patient experiences generating deeper insights and better outcomes to improve care and accelerate research. The Outcomes4Me mobile app enables cancer patients to make decisions and take control of their care based on information that is personalized to their specific condition, including finding treatment options, matching to clinical trials, and tracking and managing symptoms. Based in Boston, Massachusetts, Outcomes4Me, a woman-led company, comprises seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans. For more information, visit http://www.outcomes4me.com.

Follow this link:
Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients - Business Wire

Classical genetics and traditional breeding in cucumbers – hortidaily.com

Rapid progress has been made in classical genetics and traditional breeding in cucumber for various quantitative and qualitative traits which greatly benefited the development of superior varieties suitable for open field and protected cultivation. The different breeding methods like plant introductions, hybridizations, pedigree selection, recombination breeding, and marker-assisted selection have been employed successfully in developing superior varieties and F 1 hybrids.

The development of new varieties with earliness, high yield, and resistance to diseases (powdery mildew, downy mildew, and tolerance to the virus) through a selection of superior parental lines followed by hybridization and marker-assisted introgression of desired genes was a game-changer in cucumber breeding. The exploitation of gynoecious sex along with parthenocarpic traits in traditional breeding has created a revolution in cucumber cultivation throughout the world which enabled the adoption of cucumber crops by the farming communities on a large scale.

Molecular markers technology could be exploited to overcome the obstacle of traditional breeding by accelerating the breeding cycle and selection of desirable traits. The high-density genetic maps for various traits have been constructed in cucumber to detected quantitative traits loci (QTLs) for genetic enhancement in different market classes of cucumber. Therefore, this research highlights the concepts of genetic foundations for advancement made in cucumber breeding.

Read the complete research at http://www.researchgate.net.

Jat, Gograj & Behera, Tusar & Lata, Suman. (2021). Classical Genetics and Traditional Breeding in Cucumber (Cucumis sativus L.). 10.5772/intechopen.97593.

Excerpt from:
Classical genetics and traditional breeding in cucumbers - hortidaily.com